Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Kidney Transplantation | 25 | 2021 | 5397 | 2.45 | Why? |
| Organ Transplantation | 14 | 2021 | 2616 | 2.04 | Why? |
| Transplant Recipients | 22 | 2021 | 4982 | 1.86 | Why? |
| Tissue and Organ Procurement | 10 | 2020 | 1277 | 1.48 | Why? |
| Histocompatibility | 2 | 2019 | 53 | 1.47 | Why? |
| Living Donors | 8 | 2020 | 652 | 1.40 | Why? |
| Donor Selection | 5 | 2019 | 804 | 1.30 | Why? |
| Graft Rejection | 5 | 2021 | 1766 | 1.29 | Why? |
| Waiting Lists | 9 | 2020 | 1388 | 1.26 | Why? |
| Kidney Failure, Chronic | 11 | 2020 | 3222 | 1.16 | Why? |
| Liver Transplantation | 12 | 2021 | 2864 | 1.09 | Why? |
| Tissue Donors | 9 | 2020 | 1679 | 1.08 | Why? |
| Graft Survival | 10 | 2020 | 587 | 1.07 | Why? |
| Hospital Costs | 3 | 2019 | 274 | 0.88 | Why? |
| Immunogenicity, Vaccine | 5 | 2021 | 4624 | 0.82 | Why? |
| Abatacept | 1 | 2021 | 192 | 0.80 | Why? |
| Delayed Graft Function | 1 | 2019 | 52 | 0.77 | Why? |
| Postoperative Complications | 6 | 2020 | 5861 | 0.74 | Why? |
| Practice Patterns, Physicians' | 3 | 2020 | 4927 | 0.63 | Why? |
| Cholecystectomy | 1 | 2018 | 198 | 0.62 | Why? |
| HLA Antigens | 2 | 2019 | 830 | 0.61 | Why? |
| Organizational Policy | 1 | 2020 | 694 | 0.57 | Why? |
| Renal Insufficiency | 2 | 2021 | 810 | 0.57 | Why? |
| Colectomy | 1 | 2018 | 327 | 0.56 | Why? |
| Antibodies, Viral | 14 | 2021 | 51949 | 0.52 | Why? |
| Resource Allocation | 3 | 2020 | 1771 | 0.52 | Why? |
| Appendectomy | 1 | 2018 | 585 | 0.50 | Why? |
| Length of Stay | 3 | 2018 | 11042 | 0.46 | Why? |
| Registries | 13 | 2020 | 12327 | 0.40 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.40 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.39 | Why? |
| Musculoskeletal Diseases | 3 | 2021 | 646 | 0.39 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.32 | Why? |
| Laparoscopy | 1 | 2018 | 1532 | 0.31 | Why? |
| Patient Safety | 1 | 2021 | 4885 | 0.30 | Why? |
| Vaccines, Synthetic | 4 | 2021 | 3231 | 0.29 | Why? |
| United States | 16 | 2021 | 46150 | 0.29 | Why? |
| Follow-Up Studies | 10 | 2021 | 17020 | 0.29 | Why? |
| End Stage Liver Disease | 3 | 2018 | 418 | 0.29 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.24 | Why? |
| Frailty | 3 | 2019 | 1432 | 0.24 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.24 | Why? |
| Adult | 29 | 2021 | 244371 | 0.23 | Why? |
| Immunosuppressive Agents | 4 | 2021 | 6331 | 0.23 | Why? |
| Male | 38 | 2021 | 367725 | 0.23 | Why? |
| Female | 38 | 2021 | 380317 | 0.23 | Why? |
| Kidney Function Tests | 3 | 2018 | 520 | 0.22 | Why? |
| Rheumatic Diseases | 3 | 2021 | 2675 | 0.22 | Why? |
| Decision Support Techniques | 2 | 2018 | 903 | 0.21 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.21 | Why? |
| Immunocompromised Host | 3 | 2021 | 5150 | 0.20 | Why? |
| Healthcare Disparities | 1 | 2018 | 3893 | 0.20 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.20 | Why? |
| Mobility Limitation | 1 | 2020 | 153 | 0.19 | Why? |
| Risk Factors | 14 | 2021 | 71621 | 0.19 | Why? |
| Humans | 55 | 2021 | 930598 | 0.19 | Why? |
| Limb Salvage | 1 | 2019 | 124 | 0.19 | Why? |
| Immunoenzyme Techniques | 1 | 2021 | 448 | 0.19 | Why? |
| alpha-Fetoproteins | 1 | 2018 | 72 | 0.18 | Why? |
| Cold Ischemia | 1 | 2018 | 37 | 0.18 | Why? |
| Nephrectomy | 2 | 2019 | 406 | 0.18 | Why? |
| Transplantation | 1 | 2018 | 72 | 0.18 | Why? |
| Blood Group Incompatibility | 1 | 2017 | 44 | 0.18 | Why? |
| Antibody Formation | 5 | 2021 | 4038 | 0.17 | Why? |
| Hepatitis, Alcoholic | 1 | 2018 | 61 | 0.17 | Why? |
| Glomerular Filtration Rate | 3 | 2018 | 1262 | 0.17 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.17 | Why? |
| Hospital Mortality | 2 | 2018 | 22087 | 0.17 | Why? |
| Vision Disorders | 1 | 2020 | 260 | 0.16 | Why? |
| Hearing Loss | 1 | 2020 | 225 | 0.16 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.16 | Why? |
| Allografts | 1 | 2019 | 761 | 0.15 | Why? |
| Eligibility Determination | 1 | 2018 | 255 | 0.15 | Why? |
| Death | 1 | 2019 | 334 | 0.15 | Why? |
| Aged | 20 | 2021 | 215776 | 0.15 | Why? |
| Clinical Decision-Making | 2 | 2020 | 3755 | 0.15 | Why? |
| Risk Assessment | 7 | 2019 | 25439 | 0.14 | Why? |
| Health Plan Implementation | 1 | 2019 | 571 | 0.13 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.13 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.13 | Why? |
| Hospitals, Special | 1 | 2018 | 523 | 0.13 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.13 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2019 | 471 | 0.12 | Why? |
| Prognosis | 8 | 2020 | 32490 | 0.12 | Why? |
| RNA, Messenger | 3 | 2021 | 5131 | 0.12 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.12 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Carcinoma, Hepatocellular | 2 | 2018 | 1222 | 0.11 | Why? |
| Immune System | 1 | 2021 | 1479 | 0.11 | Why? |
| Ischemia | 1 | 2019 | 901 | 0.11 | Why? |
| Heart Transplantation | 1 | 2021 | 1293 | 0.11 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.11 | Why? |
| Hepatitis C | 2 | 2019 | 1514 | 0.11 | Why? |
| Health Care Surveys | 1 | 2020 | 2942 | 0.10 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.10 | Why? |
| Disabled Persons | 1 | 2020 | 1152 | 0.10 | Why? |
| Endovascular Procedures | 1 | 2019 | 1302 | 0.09 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.09 | Why? |
| Survival Analysis | 2 | 2019 | 7592 | 0.09 | Why? |
| Time Factors | 7 | 2019 | 31397 | 0.09 | Why? |
| Child | 5 | 2020 | 70012 | 0.09 | Why? |
| Patient Readmission | 1 | 2017 | 1543 | 0.09 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.09 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.08 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.08 | Why? |
| HIV Infections | 2 | 2021 | 11620 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Infant, Newborn | 3 | 2020 | 23105 | 0.07 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.07 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.06 | Why? |
| Infant | 3 | 2020 | 30274 | 0.06 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.06 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.06 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.06 | Why? |
| Age Factors | 2 | 2019 | 21039 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.05 | Why? |
| Preoperative Period | 1 | 2019 | 271 | 0.05 | Why? |
| Motor Activity | 1 | 2020 | 217 | 0.05 | Why? |
| Baltimore | 1 | 2018 | 220 | 0.04 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Symptom Flare Up | 1 | 2021 | 432 | 0.04 | Why? |
| Maryland | 1 | 2019 | 436 | 0.04 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.04 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 229 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| Transplants | 1 | 2018 | 136 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Amputation | 1 | 2019 | 331 | 0.04 | Why? |
| Isoantibodies | 1 | 2017 | 134 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Walking | 1 | 2020 | 442 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Cadaver | 1 | 2018 | 626 | 0.03 | Why? |
| Lower Extremity | 1 | 2019 | 593 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2019 | 15909 | 0.03 | Why? |
| Independent Living | 1 | 2018 | 842 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.03 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.03 | Why? |
| Interviews as Topic | 1 | 2019 | 1952 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.02 | Why? |
| Hepacivirus | 1 | 2019 | 1509 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Health Personnel | 1 | 2019 | 29646 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2021 | 3023 | 0.02 | Why? |
| Body Mass Index | 1 | 2019 | 4306 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2018 | 3088 | 0.02 | Why? |
| Antiviral Agents | 1 | 2019 | 41703 | 0.02 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
| Surgeons | 1 | 2018 | 2233 | 0.02 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.01 | Why? |
| Spain | 1 | 2019 | 15545 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Hospitalization | 1 | 2017 | 54280 | 0.00 | Why? |
Garonzik-Wang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(188)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(97)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_